Natasha M. Nesbitt
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$3.6MFederal grants as PI6 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
6 awards · $3.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | SBIR Phase II Development of Second Generation BLVRB Inhibitors for Treating Chemotherapy Induced Thrombocytopenia | $875K | BLOOD CELL TECHNOLOGIES LLC |
| Aug 25, 2025 | NIH | SBIR Phase II Development of Second Generation BLVRB Inhibitors for Treating Chemotherapy Induced Thrombocytopenia | $400K | BLOOD CELL TECHNOLOGIES LLC |
| Aug 10, 2023 | NIH | SBIR Phase II Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production | $613K | BLOOD CELL TECHNOLOGIES LLC |
| Jun 9, 2022 | NIH | SBIR Phase II Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production | $764K | BLOOD CELL TECHNOLOGIES LLC |
| Aug 6, 2021 | NIH | SBIR Phase II Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production | $691K | BLOOD CELL TECHNOLOGIES LLC |
| Jun 30, 2015 | NIH | SBIR Phase I Development of a biliverdin IX Beta reductase redox inhibitor for enhanced platelet production | $221K | BLOOD CELL TECHNOLOGIES LLC |
Peer ranks
Federal funding#480
Awards as PI#315
Patents#273
Companies
- BLOOD CELL TECHNOLOGIES LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.